Zacks Investment Research
27 Jan 2026, 20:10 UTC · 33w ago
Verdict
Headline takes no side. We score BHC −0.80 across four claims — strongly bearish.
−0.80strongly bearish
More negative than 87% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
Bausch Health's late-stage RED-C clinical program failed to meet its primary endpoint in phase III studies.
So whatThe failure of a late-stage trial for a major growth driver typically leads to significant valuation drops due to lost future revenue potential.
More negative than 98% of claims this week
Xifaxan, a primary revenue driver accounting for 85% of Salix revenues in early 2025, is set to lose exclusivity in the U.S. in 2028.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More negative than 91% of claims this week
Bausch Health is currently involved in multiple lawsuits regarding the generic version of Xifaxan.
So whatLegal uncertainty and potential generic entry accelerate the erosion of market share and profit margins.
More negative than 80% of claims this week
Bausch Health's aesthetics business, Solta Medical, acquired Wuhan Shibo Zhenmei Technology to expand its distribution in China.
More positive than 54% of claims this week
Which stocks this story touches
More negative than 87% of ticker scores this week
The company's shares dropped following the failure of the late-stage RED-C clinical program and ongoing lawsuits.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
6h ago
−2.2%
Price agrees with the score
$5.67 vs $5.80 close before publication (Jan 26) · not market-adjusted
BHC chart →
